Jianguo Zhou

Department of Radiation Oncology

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine (2021) Zhong H, Liu S, Cao F, Zhao Y, Zhou J, Tang F, Peng Z, et al. Journal article Low-dose Radiotherapy is highly effective in the Treatment of Patients with painful Ankle Arthrosis (2021) Weissmann T, Putz F, Hecht M, Zhou J, Donaubauer AJ, Fietkau R, Gaipl U, et al. Conference contribution Prospective Assessment of the Inflammation Parameters in Blood Counts and Blood Serum as prognostic/predictive Parameters for Treatment with Immune Checkpoint-Inhibitors (2021) Schweizer C, Haderlein M, Schubert P, Zhou J, Semrau S, Rutzner S, Gostian AO, et al. Conference contribution Low-Dose Radiotherapy is highly effective in the Treatment of painful Finger Polyarthrosis (2021) Weissmann T, Gaipl U, Putz F, Hecht M, Donaubauer AJ, Zhou J, Fietkau R, et al. Conference contribution Progress Patterns under Radioimmunotherapy - clinical Evaluation of the prospective STICI Study (2021) Schubert P, Schweizer C, Roesch J, Haderlein M, Rutzner S, Semrau S, Donaubauer AJ, et al. Conference contribution Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer (2021) Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, et al. Journal article The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, et al. Journal article, Review article The Role of ncRNAs in Solid Tumors Prognosis: From Laboratory to Clinical Utility (2021) Zhou J, Huang Z, Slaby O, Navarro A Journal article, Editorial Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies (2021) Ma SC, Tang XR, Long LL, Bai X, Zhou J, Duan ZJ, Wang J, et al. Journal article